|
Volumn 37, Issue 9, 2005, Pages 3597-3599
|
Steroid-sparing strategies
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
BASILIXIMAB;
CORTICOSTEROID;
CYCLOSPORIN A;
EVEROLIMUS;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PREDNISONE;
TACROLIMUS;
ACUTE GRAFT REJECTION;
BONE DISEASE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CATARACT;
CLINICAL TRIAL;
CONFERENCE PAPER;
CORTICOSTEROID THERAPY;
DIABETES MELLITUS;
DRUG WITHDRAWAL;
EYE DISEASE;
FOLLOW UP;
GRAFT FAILURE;
GRAFT SURVIVAL;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LONG TERM CARE;
LOW DRUG DOSE;
LYMPHOCYTE PROLIFERATION;
META ANALYSIS;
ORGAN TRANSPLANTATION;
PATIENT COMPLIANCE;
PNEUMONIA;
PRIORITY JOURNAL;
RECIPIENT;
RISK ASSESSMENT;
RISK REDUCTION;
SURVIVAL RATE;
SURVIVAL TIME;
SYSTEMATIC REVIEW;
T LYMPHOCYTE;
THROMBOSIS;
TREATMENT OUTCOME;
ADRENAL CORTEX HORMONES;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
IMMUNOSUPPRESSION;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
RANDOMIZED CONTROLLED TRIALS;
|
EID: 29544438047
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2005.09.121 Document Type: Conference Paper |
Times cited : (6)
|
References (12)
|